| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Eli Lilly and Company (XETRA: LLY)
LLY Technical Analysis
5
| As on 22nd Aug 2025 LLY STOCK Price closed @ 610.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 775.72 & Strong Sell for SHORT-TERM with Stoploss of 712.60 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LLYSTOCK Price
| Open | 610.20 | Change | Price | % |
| High | 619.50 | 1 Day | -7.30 | -1.18 |
| Low | 609.80 | 1 Week | 49.30 | 8.79 |
| Close | 610.10 | 1 Month | -58.80 | -8.79 |
| Volume | 4141 | 1 Year | -86.40 | -12.40 |
| 52 Week High 886.70 | 52 Week Low 542.00 | ||||
XETRA Germany Most Active Stocks
| LHAR | 2.05 | -20.23% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BVBA | 0.02 | -60.00% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| AMMN | 8500.00 | 1440578.00% |
| CBK | 36.46 | -3.77% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
| LLY Daily Charts |
LLY Intraday Charts |
Whats New @ Bazaartrend |
LLY Free Analysis |
|
|
LLY Important Levels Intraday
| RESISTANCE | 628.79 |
| RESISTANCE | 622.80 |
| RESISTANCE | 619.09 |
| RESISTANCE | 615.39 |
| SUPPORT | 604.81 |
| SUPPORT | 601.11 |
| SUPPORT | 597.40 |
| SUPPORT | 591.41 |
LLY Forecast August 2025
| 4th UP Forecast | 771 |
| 3rd UP Forecast | 719.4 |
| 2nd UP Forecast | 687.5 |
| 1st UP Forecast | 655.61 |
| 1st DOWN Forecast | 564.59 |
| 2nd DOWN Forecast | 532.7 |
| 3rd DOWN Forecast | 500.8 |
| 4th DOWN Forecast | 449.2 |
LLY Weekly Forecast
| 4th UP Forecast | 677.55 |
| 3rd UP Forecast | 655.92 |
| 2nd UP Forecast | 642.55 |
| 1st UP Forecast | 629.18 |
| 1st DOWN Forecast | 591.03 |
| 2nd DOWN Forecast | 577.66 |
| 3rd DOWN Forecast | 564.29 |
| 4th DOWN Forecast | 542.66 |
LLY Forecast2025
| 4th UP Forecast | 1289.37 |
| 3rd UP Forecast | 1071.52 |
| 2nd UP Forecast | 936.87 |
| 1st UP Forecast | 802.21 |
| 1st DOWN Forecast | 417.99 |
| 2nd DOWN Forecast | 283.33 |
| 3rd DOWN Forecast | 148.68 |
| 4th DOWN Forecast | -69.17 |
Eli Lilly and Company ( XETRA Germany Symbol : LLY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LLY Business Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute, as well as Kumquat Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service